png440x100.png){kind=logo}
News Releases
Contact Us
We welcome all announcements related to new therapies, organizational events, and partnerships with GlomCon. If you have exciting news to share or would like to discuss collaboration opportunities, please get in touch with info@glomcon.org.
Travere receives FULL FDA approval for Filspari (Sparsentan) for IgA nephropathy.
Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to FILSPARI® (sparsentan) to slow kidney function decline in adults with primary IgAN who are at risk of disease progression.
SEPTEMBER 05, 2024
GlomCon Foundation and Baim Institute for Clinical Research Enter Research Collaboration Agreement
This partnership, built with complementary backgrounds and shared goals, aims to leverage both organizations' unique strengths to support the design and implementation of large, real-world evidence studies, global registries, and randomized controlled trials.
JUNE 6, 2024